组卷网 > 高中英语综合库 > 主题 > 人与自我 > 健康 > 医疗
题型:阅读理解-阅读单选 难度:0.65 引用次数:59 题号:17863345

The word “syringe (注射器)” comes from the Greek word syrinx, meaning “tube”.

The first syringe was used in Roman times during the 1st century. It was mentioned in a journal called De Medicina as being used to treat diseases. Then, in the 9th century, an Egyptian surgeon created a syringe using a glass tube.

In 1650 Blaise Pascal invented a syringe as an application of fluid mechanics that is now called Pascal’s law. He used it for testing his theory about pressure.

An Irish physician named Francis Rynd made the first recorded subcutaneous injection (皮下 注射) in I844. Then shortly thereafter in 1853 Charles Pravaz and Alexander Wood developed a medical syringe with a needle fine enough to give an injection under the skin and treat nerve conditions.

In 1899 Letitia Mumford Geer of New York was issued with a patent for a syringe design that permitted the user to operate it one-handed. However, things got more interesting and advanced in 1946 when Chance Brothers in England produced the first all-glass syringe with an interchangeable barrel and plunger (筒和活塞). This was • revolutionary because it allowed the mass-sterilization (大规模消毒) of the different components without needing to match up the individual parts.

Shortly thereafter Australian inventor Charles Rothauser created the world’s first plastic disposable (一次性的) syringe at his Adelaide factory in1949. However, because the plastic used by Rothauser softened with heat, the syringes had to be chemically dealt with before packaging, which made them expensive. Two years later he improved syringes that can be dealt with by heat. Millions were made for Australian and export markets.

Then in 1956 a New Zealand inventor Colin Murdoch was issued with patents for a disposable plastic syringe. It was closely followed by the Plastipak-a plastic disposable syringe introduced by Becton Dickinson in1961. In 1974 African American inventor Phil Brooks received a US patent for a “Disposable Syringe”.

These days syringes are used, not only in the medical and health industry, but in various other areas too.

1. What happened before 1853?
A.Pascal’s law was tested in practice.
B.An Egyptian surgeon created the first syringe.
C.De Medicina introduced a syringe using a glass tube.
D.Charles Pravaz used a syringe to treat nerve conditions.
2. What can be learned about the patents for the syringe?
A.An all-glass syringe was patented in 1844.
B.A one-handed syringe was patented in 1899.
C.A US patent for a “Disposable Syringe” was issued in 1961.
D.A disposable plastic syringe was first patented in 1974.
3. Who made the syringe mass-produced in Australia?
A.Francis Rynd.B.Alexander Wood.C.Chance Brothers.D.Charles Rothauser.
4. What is the best title for the text?
A.The history of the syringe
B.The significance of the syringe
C.The characteristics of the syringe
D.The classification of the syringe

相似题推荐

阅读理解-阅读单选(约360词) | 适中 (0.65)
名校

【推荐1】China will give the green light to Internet medical services conducted by medical institutions as part of a broader push to promote Internet Plus Healthcare, those at a State Council executive meeting chaired by Premier Li Keqiang decided.

Medical institutions will be allowed to provide online diagnostic services for some common and chronic diseases in patients' follow-up visits to their doctors. The top levels of hospitals will be encouraged to provide online services, including consultations (会诊), reservations and test result inquiries.

As China joins the ranks of middle-income countries, the demand for health services has increased accordingly. Internet Plus Healthcare can help reduce the problem of inaccessible and expensive public health services that have long been a big concern for the general public.

One decision coming out of the meeting says the intelligent review for health insurance will be applied and the one-stop settlement will be advanced. The real-time sharing of prescription and drug retail sales will be explored, as well.

“We must waste no time in pushing forward the measures once the decisions made.” Li said. “In recent years, top-level hospitals in major cities have seen steady increases in the number of patients. Medical bills have become a heavy burden on families and high-end medical resources still fall short of meeting the growing demand of the public.”

To solve the problem, a two-pronged (双管齐下的) approach must be taken. One is to establish medical partnerships to strengthen cooperation between major hospitals and community clinics. The other is to bring forward Internet Plus Healthcare to promote the sharing of quality medical resources.

The government will see to it that long-distance healthcare services cover all county-level hospitals. So more efforts will be made to ensure that high-speed broadband network will be extended to cover medical institutions in urban and rural areas. Dedicated internet access services will be set up to meet the needs for long-distance healthcare services.

1. According to the text, which of the following services won’t a patient enjoy online?
A.Receiving a medical operation.
B.Asking doctors for advice after the test.
C.Several doctors discussion about the disease.
D.Making an appointment with a doctor in advance.
2. Why is the demand for health services increasing in China?
A.The expense of medical care.
B.The recognition of health insurance.
C.The improvement of people's life quality.
D.The inconvenience of hospital equipment.
3. What does Li mean by saying “We must waste no time in pushing forward the measures”?
A.The bills are impossible to afford.
B.The situations are urgent to improve.
C.The measures are perfectly worked out,
D.The hospitals are unwilling to admit patients.
4. What can be the suitable title for the text?
A.Modern Hospitals
B.Online Healthcare on its Way
C.No More Burden for General People
D.Wide Applications of Internet Service
2018-06-13更新 | 345次组卷
阅读理解-阅读单选(约390词) | 适中 (0.65)
名校
文章大意:这是一篇说明文,文章主要讲述科学家们在世界上首次将实验室制造的红细胞输进一名人类志愿者体内,专家们认为这项试验对患有罕见血液病的人有巨大的潜力。

【推荐2】Scientists have transfused (输血) lab-made red blood cells into a human volunteer in a world-first trial that experts say has major potential for people with hard-to-match blood types or conditions such as sickle cell disease. The research could someday mean an end to long searches for compatible donors (匹配的捐赠者) or dangerous transfusion reactions.

The experimental transfusion was done at Addenbrooke’s Hospital in Cambridge, England, as part of a joint effort among UK scientists to understand how lab-made blood transfusions could work.

The scientists took whole blood from donors in a UK database and separated out the stem cells. These are the body’s raw materials — the cells from which all specialized cells,like a red blood cell, can generate.Researchers grew red blood cells from those stem cells and transfused them into two healthy volunteers.

The transfusions involved only a tiny amount of blood: about one or two teaspoons. A standard blood transfusion would involve many hundred times that amount. This stage of the trial involves two mini transfusions at least four months apart, one with a standard donation of red cells and the other with lab-made cells from the same donor.

The researchers are closely monitoring the volunteers to determine whether the process was safe. They say there have been with“no unexpected side effects” so far. They’re also watching how long the lab-grown cells last compared with an infusion of standard red blood cells. Red blood cells typically last about 120 days, but a transfusion from a standard donation contains cells that are a variety of ages because the bone marrow (骨髓) continuously makes these cells.

Previous tests have shown that manufactured cells function like normal cells and that these lab-made cells are likely to survive longer overall while in circulation. This study will determine for the first time whether that’s true.

Further trials will be necessary to determine whether there could be a clinical use of this lab-grown product.

The research could eventually make a difference for people with sickle cell disease, those who. develop antibodies against most donor blood types, or those with genetic disorders in which their bod can’t make red blood cells or the blood cells they make don’t work well.

1. What is the purpose of the experiment?
A.To seek out hard-to-match blood types.
B.To end dangerous transfusion reactions.
C.To promote close cooperation among UK scientists.
D.To know how to transfuse lab-grown blood effectively.
2. What do we know about the lab-made cells?
A.They typically last about four months.
B.They were grown from red blood cells.
C.They did unexpectedly cause some side effects.
D.They were transfused into a volunteer in large amounts.
3. What’s the author’s attitude towards the research?
A.Indifferent.B.Disapproving.C.Suspicious.D.Favourable.
4. What is the text mainly about?
A.Lab-made cells function normally and are likely to survive longer in circulation.
B.Lab-grown blood could have enormous potential for people with rare blood conditions.
C.Long searches for compatible donors and dangerous transfusion reactions can be ended.
D.An experimental transfusion was done at Addenbrooke’s Hospital in Cambridge, England.
2023-03-27更新 | 101次组卷
阅读理解-阅读单选(约330词) | 适中 (0.65)
名校
文章大意:本文为一篇说明文,主要介绍了研究人员发现章鱼的毒液可能会大大减慢癌症的生长,并有助于对抗患有BRAF变异皮肤癌患者的药物抵抗力。目前,章鱼毒液的应用需要进一步的工作。

【推荐3】The Australian sand octopus (章鱼) was discovered in 1990 and is the only octopus species known to bury itself deep in the sand to hide from enemies. A team of researchers are studying the venom (毒液) of this kind of octopus. They have discovered that the venom may greatly slow cancer growth. And it can also help fight drug resistance in patients with a BRAF-changed skin cancer. BRAF is involved in managing cell growth. A change in it results in abnormal cell growth. These BRAF changes are seen in half of all cases of skin cancers.

“We and other groups have previously discovered that other animals-snakes, spiders, bees-have anticancer properties,” said Dr. Maria, the study’s lead author. “However, in my current knowledge, the anticancer properties of an octopus species have never been studied or confirmed before.”

Current treatments face a few challenges including low response rates, poisoning and side effects, as well as drug resistance. The octopus venom slows the growth of BRAF-changed skin cancer. More importantly, it is safe to be used in large quantities — it is not poisonous. Therefore, in combination with other drugs, the treatments could potentially achieve better and safer patient outcomes.

It is very unlikely that the octopus has specifically developed its venom to contain an anticancer substance. According to the researching team, the octopus venom contains over 1,000 unique substances with several functions such as reducing pain and anticancer.

“In this study, we have shown that the octopus venom specifically targets BRAF-changed skin cancer. The next step is to examine whether similar promising results are applicable for other BRAF-changed cancers.” said Dr. Maria. “Before it can be used on patients, the team will need to perform several rounds of lab testing and clinical trials to understand how it works and its full potential as a drug against skin cancer.”

1. What can we know about BRAF?
A.It is a change in cells.B.It controls cell growth.
C.It can cause a deadly illness.D.It helps to cure a skin cancer.
2. What discovery did the team make?
A.A medicine to cure cancers.B.A substance contained in animals.
C.The medical value of octopus species.D.The anticancer effect of an octopus venom.
3. What is an advantage of the octopus venom to treat the skin cancer?
A.It is of large quantity.B.It has no side effects.
C.It is less expensive.D.It has lower risks.
4. What can we infer from the last paragraph concerning the octopus venom?
A.Its application requires further work.
B.It helps treat BRAF-changed cancers.
C.Its safety needs more clinical testings.
D.It has already been put into wide use.
2024-02-16更新 | 65次组卷
共计 平均难度:一般